



JC03 F PCT/PTC 23 JAN 2002 PET #3  
09/914324

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|   |   |                        |
|---|---|------------------------|
| In re Application of                          | ) |                        |
| Conaway <i>et. al.</i>                        | ) | Art Unit:              |
| Serial No. 09/914,324                         | ) | Examiner: K. Baltimore |
| Int. App. No. PCT/US00/04838                  | ) | December 21, 2001      |
| Int. Filing Date: 25 February 2000 (25-02-00) | ) | OMRF1001               |
| Title: Novel Component of Von Hippel-Lindau   | ) |                        |
| Tumor Suppressor Complex and                  |   |                        |
| SCF Ubiquitin Ligase                          |   |                        |

TRANSMITTAL LETTER

Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

Transmitted herewith are (1) a Change In Correspondence Address, (2) a copy of the "Notification of Missing Requirements Under 35 U.S.C. 371 in The United States Designated/Elected Offices (DO/EO/US)", and (3) a Response to the "Notification of Missing Requirements Under 35 U.S.C. 371 in The United States Designated/Elected Offices (DO/EO/US)."

Please charge any fees required in connection with the Response or any fees required during the entire pendency of this Application to Deposit Account No. 500449.

Respectfully submitted,

*Wendell Ray Guffey*

Wendell Ray Guffey  
Reg. No. 31,762  
Phone: 812-842-2068

6799 River Ridge Drive  
Newburgh, Indiana 47630

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited in the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on December 21, 2001.

*Wendell Ray Guffey*  
Wendell Ray Guffey



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|   |   |                        |
|---|---|------------------------|
| In re Application of                          | ) |                        |
| Conaway <i>et. al.</i>                        | ) | Art Unit:              |
| Serial No. 09/914,324                         | ) | Examiner: K. Baltimore |
| Int. App. No. PCT/US00/04838                  | ) | December 21, 2001      |
| Int. Filing Date: 25 February 2000 (25-02-00) | ) | OMRF1001               |
| Title: Novel Component of Von Hippel-Lindau   | ) |                        |
| Tumor Suppressor Complex and                  |   |                        |
| SCF Ubiquitin Ligase                          |   |                        |

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER  
35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED  
OFFICES (DO/EO/US)**

Box Missing Parts  
Commissioner of Patents  
and Trademarks  
Washington, DC 20231

Sir:

This Paper is in response to the "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICES (DO/EO/US)" dated October 30, 2001.


The above Application is based upon International Application No. PCT/US00/04838 with an International Filing Date of 25 February 2000 (25-02-00) and a Priority Date of 26 February 1999 (26-02-99). A computer readable form (CFR) of the "Sequence Listing" was submitted with such International Application. Please transfer the CFR of the "Sequence Listing" from that Application to be used with the U.S. Application identified above.

The paper copy of the Sequence Listing is in the U.S. Application identified above. The paper copy and the CFR to be transferred are identical. The content of the paper and computer readable copy is the same.

This submission includes no new matter and does not go beyond the disclosure in the international application as filed.


**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited in the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on December 21, 2001.

  
Wendell Ray Guffey

6799 River Ridge Drive  
Newburgh, Indiana 47630

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Wendell Ray Guffey".

Wendell Ray Guffey  
Reg. No. 31,762  
Phone: 812-842-2068


|  |  |  |
|--|--|--|
|        |  |  |
| <small>U.S. Patent and Trademark Office, Washington, D.C. 20231, www.uspto.gov</small> |  |  |

|                             |                       |                  |
|-----------------------------|-----------------------|------------------|
| U.S. APPLICATION NUMBER NO. | FIRST NAMED APPLICANT | ATTY. DOCKET NO. |
| 09/914,324                  | Joan W. Conaway       | OMRF 1001        |

|                               |               |
|-------------------------------|---------------|
| INTERNATIONAL APPLICATION NO. |               |
| PCT/US00/04838                |               |
| I.A. FILING DATE              | PRIORITY DATE |
| 02/25/2000                    | 02/26/1999    |

Wendell Ray Guffey  
Mead Johnson & Company  
2400 West Lloyd Expressway  
Mail Stop A 21  
Evansville, IN 47721-0001

**CONFIRMATION NO. 3570**  
**371 FORMALITIES LETTER**



Date Mailed: 10/30/2001

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

**RECEIVED**  
**NOV 6 2001**  
**PATENT DEPARTMENT**

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason (s):
  - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
  - **APPLICANT MUST PROVIDE:**
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as

an amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

KAYA L LEWIS BALTIMORE

Telephone: (703) 305-3695

**PART 1 - ATTORNEY/APPLICANT COPY**

3619 Donna Green

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO. |
|-----------------------------|-------------------------------|------------------|
| 09/914,324                  | PCT/US00/04838                | OMRF 1001        |